Literature DB >> 7824975

Classification of histopathologic changes following chemotherapy in Ewing's sarcoma of bone.

H J van der Woude1, J L Bloem, A H Taminiau, M A Nooy, P C Hogendoorn.   

Abstract

A uniform classification of response to chemotherapy is essential to allow comparison of local effect and ultimate prognosis between different therapy schedules. We define a histological grading system for assessment of the response to chemotherapy in Ewing's sarcoma, based on the amount and architectural pattern of residual histologically viable-appearing tumour, the preferential sites of minimal residual tumour and the amount of tumour necrosis. Twenty-six consecutive patients with a biopsy-proven Ewing's sarcoma were treated with chemotherapy prior to surgery. The effect of chemotherapy was evaluated microscopically on the specimens obtained after surgery. Response to chemotherapy was classified as minimal or no effect (< 10% tumour necrosis), moderate effect (solid areas of remnant viable tumour), minimal residual disease, and no evidence of disease (100% tumour necrosis or well-vascularized fibrous tissue). The subperiosteal area in particular and, less frequently, soft tissues and intramedullary compartment were identified as sites of predilection for persistence of microscopic viable tumour foci, frequently depicted as pseudo-rosettes in a characteristic scattered pattern. Although it is not well known whether morphological viability of these residual clusters in Ewing's sarcoma indicates biological viability, accurate preoperative local staging, with special attention to preferential sites of residual viable tumour, is essential. The proposed grading system can be used to standardize assessment of chemotherapy in trials, and may serve as a standard for non-invasive monitoring of preoperative chemotherapy with magnetic resonance imaging.

Entities:  

Mesh:

Year:  1994        PMID: 7824975     DOI: 10.1007/bf00223077

Source DB:  PubMed          Journal:  Skeletal Radiol        ISSN: 0364-2348            Impact factor:   2.199


  23 in total

1.  Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response.

Authors:  K Winkler; G Beron; G Delling; U Heise; H Kabisch; C Purfürst; J Berger; J Ritter; H Jürgens; V Gerein
Journal:  J Clin Oncol       Date:  1988-02       Impact factor: 44.544

2.  The response of Ewing's sarcoma to sequential cyclophosphamide and adriamycin induction therapy.

Authors:  F A Hayes; E I Thompson; H O Hustu; M Kumar; T Coburn; B Webber
Journal:  J Clin Oncol       Date:  1983-01       Impact factor: 44.544

3.  Chemotherapy for osteogenic sarcoma: an investigative method, not a recipe.

Authors:  G Rosen; A Nirenberg
Journal:  Cancer Treat Rep       Date:  1982-09

Review 4.  The effect of therapy on tumour vascular function.

Authors:  D J Chaplin
Journal:  Int J Radiat Biol       Date:  1991 Jul-Aug       Impact factor: 2.694

5.  Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement.

Authors:  A G Huvos; G Rosen; R C Marcove
Journal:  Arch Pathol Lab Med       Date:  1977-01       Impact factor: 5.534

6.  Malignant peripheral neuroectodermal tumor and its necessary distinction from Ewing's sarcoma. A report from the Kiel Pediatric Tumor Registry.

Authors:  D Schmidt; C Herrmann; H Jürgens; D Harms
Journal:  Cancer       Date:  1991-11-15       Impact factor: 6.860

7.  Long-term results in 144 localized Ewing's sarcoma patients treated with combined therapy.

Authors:  G Bacci; A Toni; M Avella; M Manfrini; A Sudanese; D Ciaroni; S Boriani; E Emiliani; M Campanacci
Journal:  Cancer       Date:  1989-04-15       Impact factor: 6.860

8.  Prognostic value of histopathology in Ewing's sarcoma. Long-term follow-up of distal extremity primary tumors.

Authors:  K R Hartman; T J Triche; T J Kinsella; J S Miser
Journal:  Cancer       Date:  1991-01-01       Impact factor: 6.860

9.  Monitoring the effect of chemotherapy in Ewing's sarcoma of bone with MR imaging.

Authors:  H J van der Woude; J L Bloem; H C Holscher; M A Nooy; A H Taminiau; J Hermans; T H Falke; P C Hogendoorn
Journal:  Skeletal Radiol       Date:  1994-10       Impact factor: 2.199

10.  Neoadjuvant chemotherapy for localized Ewing's sarcoma of the extremities: preliminary results of a protocol which uses surgery (alone or followed by radiotherapy) for local control.

Authors:  G Bacci; D Dallari; D McDonald; M Avella; A Toni; E Barbieri; D Ciaroni; A Sudanese; A Mancini; A Giunti
Journal:  Tumori       Date:  1989-10-31
View more
  6 in total

1.  Adamantinoma-like Ewing's sarcoma with EWS-FLI1 fusion gene: a case report.

Authors:  Hiromasa Fujii; Kanya Honoki; Yasunori Enomoto; Takahiko Kasai; Akira Kido; Itsuto Amano; Makiko Kumamoto; Toru Morishita; Yoshio Mii; Akitaka Nonomura; Yoshinori Takakura
Journal:  Virchows Arch       Date:  2006-10-03       Impact factor: 4.064

2.  Monitoring the effect of chemotherapy in Ewing's sarcoma of bone with MR imaging.

Authors:  H J van der Woude; J L Bloem; H C Holscher; M A Nooy; A H Taminiau; J Hermans; T H Falke; P C Hogendoorn
Journal:  Skeletal Radiol       Date:  1994-10       Impact factor: 2.199

3.  Histopathologic and Radiologic Assessment of Chemotherapeutic Response in Ewing's Sarcoma: A Review.

Authors:  José M García-Castellano; Nagib Atallah Yordi; Carolina Reyes; John H Healey
Journal:  Sarcoma       Date:  2012-03-01

4.  Guidelines for histopathological specimen examination and diagnostic reporting of primary bone tumours.

Authors:  D Charles Mangham; Nicholas A Athanasou
Journal:  Clin Sarcoma Res       Date:  2011-07-25

5.  Serum levels of IGF-1 and IGF-BP3 are associated with event-free survival in adult Ewing sarcoma patients treated with chemotherapy.

Authors:  Stefanie de Groot; Hans Gelderblom; Marta Fiocco; Judith Vmg Bovée; Jacobus Jm van der Hoeven; Hanno Pijl; Judith R Kroep
Journal:  Onco Targets Ther       Date:  2017-06-13       Impact factor: 4.147

6.  Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis.

Authors:  Dagmar Berghuis; Marco W Schilham; Hanneke I Vos; Susy J Santos; Stephan Kloess; Emilie P Buddingh'; R Maarten Egeler; Pancras Cw Hogendoorn; Arjan C Lankester
Journal:  Clin Sarcoma Res       Date:  2012-02-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.